化合物 FX1|T4089|TargetMol

價格	￥152	￥212	￥373
包裝	1mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 FX1	英文名稱:FX1
CAS:1426138-42-2	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 98.15%	產(chǎn)品類別: 抑制劑
貨號: T4089

Product Introduction

Bioactivity

名稱	FX1
描述	FX1 is an effective and selective BCL6 inhibitor (IC50: 35 μM).
細(xì)胞實驗	Cell viability is determined with the fluorescent redox dye. Fluorescence is determined for 3 replicates per treatment condition or vehicle with the microplate reader. The drug effect as 100-percentage viability is calculated. Through dose-effect curves the drug concentration that inhibits the growth of cell lines by 50% compared with vehicle (GI50) is determined. Experiments are performed in triplicate. For combination treatments, cells are exposed to a dose curve of each drug alone or their combination in a constant ratio, and cell viability is determined. To compare different schedules of treatments, the cells are treated in triplicate as follows: FX1 and doxorubicin simultaneously and cells treated for 48 hours; FX1 first and 24 hours after doxorubicin is added and treats for an extra 48 hours; doxorubicin first and 24 hours after FX1 is added and treats for an extra 48 hours. Then, the software is used to plot dose-effect curves and calculate the dose-reduction index [1].
動物實驗	Cell viability is determined with the fluorescent redox dye. Fluorescence is determined for 3 replicates per treatment condition or vehicle with the microplate reader. Cell viability of the drug-treated cells is normalized to their vehicle-treated controls, and the results are expressed as percentage viability. The drug effect as 100-percentage viability is calculated. Through dose-effect curves the drug concentration that inhibits the growth of cell lines by 50% compare with vehicle (GI50) is determined. Experiments are performed in triplicate. For combination treatments, cells are exposed to a dose curve of each drug alone or their combination in constant ratio, and cell viability is determined. To compare different schedules of treatments, the cells are treated in triplicate as follows: FX1 and doxorubicin simultaneously and cells treated for 48 hours; FX1 first and 24 hours after doxorubicin is added and treats for an extra 48 hours; doxorubicin first and 24 hours after FX1 is added and treats for an extra 48 hours. Then, the software is used to plot dose-effect curves and calculate the dose-reduction index[1].
體外活性	FX1顯著降低了SMRT和BCOR對所有三個BCL6靶基因的招募。在BCL6陰性的DLBCL細(xì)胞系中，這些位點幾乎不含SMRT，且不受FX1影響。經(jīng)過50 μM FX1處理6小時后，與79-6相比，F(xiàn)X1在定量ChIP試驗中打破BCL6與SMRT結(jié)合的優(yōu)越性在DLBCL細(xì)胞的頭對頭比較中變得明顯。
體內(nèi)活性	FX1對總B細(xì)胞的豐度沒有影響。FX1顯著消耗生發(fā)中心B細(xì)胞（GL7+FAS+B220+）。用B220抗體染色揭示了正常的B細(xì)胞濾泡結(jié)構(gòu)，而針對生發(fā)中心B細(xì)胞特異性標(biāo)記的花生凝集素染色顯示GCs的顯著喪失。半衰期估計為大約12小時。與對照組相比，用FX1處理的小鼠固定器官的脾臟、肺、胃腸道、腎、心臟、肝臟和骨髓的H&E染色切片未見毒性、炎癥或感染跡象。
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 25 mg/mL (67.79 mM), Sonication is recommended.
關(guān)鍵字	inhibit \| Apoptosis \| Bcl-2 Family \| FX-1 \| FX1 \| FX 1 \| Inhibitor
相關(guān)產(chǎn)品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相關(guān)庫	抑制劑庫 \| 經(jīng)典已知活性庫 \| 抗癌化合物庫 \| 已知活性化合物庫 \| 轉(zhuǎn)錄因子庫 \| 線粒體靶向庫 \| 細(xì)胞凋亡化合物庫 \| 抗衰老化合物庫 \| 高選擇性抑制劑庫 \| PPI抑制劑庫

關(guān)鍵字： FX1|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計算機(jī)輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊資本	566.265100萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 GK921|T3968|TargetMol

￥565

化合物 Bevantolol|T61138|TargetMol

￥13800

化合物 Rbin-1|T7411|TargetMol

￥283